Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Downgrades Akero Therapeutics to Neutral, Lowers Price Target to $54

Author: Benzinga Newsdesk | October 10, 2025 05:56am
HC Wainwright & Co. analyst Andrew S. Fein downgrades Akero Therapeutics (NASDAQ:AKRO) from Buy to Neutral and lowers the price target from $72 to $54.

Posted In: AKRO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist